CERO Therapeutics Holdings, Inc. announced on November 11, 2024, the presentation of encouraging preclinical data for its lead compound, CER-1236. The data was showcased in a poster at the Society for Immunotherapy of Cancer (SITC) 2024 conference, held from November 6-10, 2024.
The study demonstrated CER-1236's capability to kill ovarian cancer cells in preclinical models without indications of toxicity in animal models. Investigators assessed CER-1236 on the immune receptor TIM-4-L in ovarian cancer cell lines, observing an increase in TIM-4-L expression followed by the killing of cancer cells.
The findings indicated CER-1236's specificity to TIM-L-4 and a lack of association with clinically relevant toxicity. This suggests that CER-1236 may be an attractive option for treating ovarian cancer, potentially expanding its utility beyond hematological malignancies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.